2,2-二苯基丙二酸 | 5457-11-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2,2-二苯基丙二酸
• 英文名称: diphenyl-malonic acid
• 英文别名: Diphenyl-malonsaeure；Diphenylmalonsaeure；Diphenylpropanedioic acid；2,2-diphenylpropanedioic acid
• CAS: 5457-11-4
• 化学式: C₁₅H₁₂O₄
• 分子量: 256.258
• InChiKey: YJGUVTBNQCVSQB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2917399090

反应信息

• 作为反应物：
  描述：

  2,2-二苯基丙二酸 在 lithium aluminium tetrahydride 、 乙醚 作用下， 生成 2,2-二苯基-1,3-丙烷二醇
  参考文献：
  名称：

  Antispasmodics. IX. β-Diethylaminoethyl Esters of Substituted α-Aryl-β-hydroxypropionic Acids

  摘要：

  DOI：

  10.1021/ja01127a036
• 作为产物：
  描述：

  2,2-二苯基丙二酰二氯 在 水 作用下， 生成 2,2-二苯基丙二酸
  参考文献：
  名称：

  丙二酸二苯酯

  摘要：

  本文没有摘要。

  DOI：

  10.1002/hlca.193501801199

文献信息

• [EN] PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES<br/>[FR] ANTAGONISTES DE RECEPTEUR DE LA PROSTAGLANDINE D2 POUR LE TRAITEMENT DE MALADIES INFLAMMATOIRES
  申请人：MILLENNIUM PHARM INC

  公开号：WO2005100321A1

  公开（公告）日：2005-10-27

  Disclosed herein are compounds represented by Structural Formula: (I) and (I-A). Also disclosed is the use of such compounds for inhibiting the G-protein coupled receptor referred to as chemoattractant receptor-homologous molecule expressed on Th2, or simply 'CRTH2' for the treatment of inflammatory disorders. The variables in Structural Formula (I) and (I-A) are defined herein.

  本文披露了由结构式(I)和(I-A)表示的化合物。还披露了利用这些化合物抑制称为趋化剂受体同源分子表达在Th2上的G蛋白偶联受体，简称为'CRTH2'，用于治疗炎症性疾病。结构式(I)和(I-A)中的变量在此处被定义。
• PGD2 receptor antagonists for the treatment of inflammatory diseases
  申请人：Ghosh Shomir

  公开号：US20050256158A1

  公开（公告）日：2005-11-17

  Disclosed herein are compounds represented by Structural Formula (I) and (I-A): Also disclosed is the use of such compounds for inhibiting the G-protein coupled receptor referred to as chemoattractant receptor-homologous molecule expressed on Th2, or simply “CRTH2” for the treatment of inflammatory disorders. The variables in Structural Formula (I) and (I-A) are defined herein.

  本文揭示了由结构式（I）和（I-A）表示的化合物：还披露了利用这些化合物抑制称为Th2表达的G蛋白偶联受体的化学引诱受体同源分子，简称“CRTH2”，用于治疗炎症性疾病。结构式（I）和（I-A）中的变量在此处被定义。
• Synthesis of triazole compounds that modulate HSP90 activity
  申请人：Chimmanamada Dinesh U.

  公开号：US20080125587A1

  公开（公告）日：2008-05-29

  The present invention provides novel methods of preparing triazole compounds which inhibit the activity of Hsp90. One embodiment of the invention is directed to methods for preparing a triazole compound represented by the following Structural Formula: or a tautomer, a pharmaceutically acceptable salt, solvate, or clathrate, or a prodrug thereof, comprising the steps of: a) reacting an amide represented by the following Structural Formula: with a thionation reagent to form a thioamide; b) reacting the thioamide of step a) with hydrazine to form a hydrazonamide; c) reacting the hydrazonamide of step b) with a carbonylation or a thiocarbonylation reagent. In one embodiment, the present invention is a method of synthesis of a compound of formula (IA) or a tautomer, a pharmaceutically acceptable salt, solvate, or clathrate, or a prodrug thereof, comprising reacting a compound of formula (IIA) with an oxidizing agent, thereby producing a compound of formula (IA). The present invention is also directed to a method of preparing a compound or a tautomer thereof represented by the following Structural Formula: or a tautomer, a pharmaceutically acceptable salt, solvate, or clathrate, or a prodrug thereof. The method comprises the step of reacting a first starting compound represented by the following Structural Formula: in the presence of a mercuric salt, with a second starting compound represented by the following Structural Formula:

  本发明提供了制备三唑化合物的新方法，该化合物抑制Hsp90的活性。发明的一种实施例涉及制备由以下结构式表示的三唑化合物的方法：或其互变异构体、药学上可接受的盐、溶剂合物、包合物或前药，包括以下步骤：a)将由以下结构式表示的酰胺与硫化试剂反应以形成硫酰胺；b)将步骤a)中的硫酰胺与肼反应以形成肼酰胺；c)将步骤b)中的肼酰胺与羰基化试剂或硫代羰基化试剂反应。在一个实施例中，本发明是一种合成公式(IA)的化合物的方法：或其互变异构体、药学上可接受的盐、溶剂合物、包合物或前药，包括将公式(IIA)的化合物与氧化剂反应，从而产生公式(IA)的化合物。本发明还涉及一种制备由以下结构式表示的化合物或其互变异构体的方法：或其互变异构体、药学上可接受的盐、溶剂合物、包合物或前药。该方法包括在汞盐的存在下，将由以下结构式表示的第一起始化合物与由以下结构式表示的第二起始化合物反应。
• Synthesis of taxol enhancers
  申请人：Shionogi BioResearch Corp.

  公开号：US20030069225A1

  公开（公告）日：2003-04-10

  Disclosed is a method of preparing a thiohydrazide product compound from a hydrazide starting compound. The hydrazide starting compound is represented by Structural Formula (I): 1 The thiohydrazide product compound is represented by Structural Formula (II): 2 In Structural Formulas (I)-(II), R 1 and R 2 are independently an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or R 1 and R 2 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. When R 2 is an aryl group or a substituted aryl group, then R 5 is a hydrazine protecting group; and when R 2 is an aliphatic or substituted aliphatic group, then R 5 is —H or a hydrazine protecting group. R 10 is —H or a substituted or unsubstituted alkyl group. The method comprising the step of reacting the starting compound with a thionylating reagent.

  本发明涉及一种从一个酰肼起始化合物制备硫代酰肼产物化合物的方法。所述酰肼起始化合物由结构式（I）表示：1 所述硫代酰肼产物化合物由结构式（II）表示：2 在结构式（I）-（II）中，R1和R2分别独立地是脂肪基，取代的脂肪基，芳基或取代的芳基，或者R1和R2连同它们连接的碳和氮原子形成一个非芳杂环环，该杂环可以与一个芳环融合。当R2是芳基或取代的芳基时，R5是一个肼保护基；当R2是脂肪基或取代的脂肪基时，R5是-H或肼保护基。R10是-H或取代或未取代的烷基。所述方法包括将起始化合物与硫酰化试剂反应的步骤。
• PROCESS FOR PREPARING BIS(THIOHYDRAZIDE AMIDES)
  申请人：Chen Shoujun

  公开号：US20110098476A1

  公开（公告）日：2011-04-28

  Disclosed herein are methods of preparing a bis(thio-hydrazide amides) compounds of the following structural formula: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 13 are defined herein.

  本文公开了一种制备下列结构式的双(硫酰肼酰胺)化合物的方法：其中R1、R2、R3、R4、R5、R6和R13在此定义。